WO2000042212A1 - Optimized high-throughput analytical system - Google Patents
Optimized high-throughput analytical system Download PDFInfo
- Publication number
- WO2000042212A1 WO2000042212A1 PCT/US2000/001268 US0001268W WO0042212A1 WO 2000042212 A1 WO2000042212 A1 WO 2000042212A1 US 0001268 W US0001268 W US 0001268W WO 0042212 A1 WO0042212 A1 WO 0042212A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- channel
- microfiuidic
- test compound
- plug
- less
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
- B01F33/302—Micromixers the materials to be mixed flowing in the form of droplets
- B01F33/3021—Micromixers the materials to be mixed flowing in the form of droplets the components to be mixed being combined in a single independent droplet, e.g. these droplets being divided by a non-miscible fluid or consisting of independent droplets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
- B01F33/3039—Micromixers with mixing achieved by diffusion between layers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44743—Introducing samples
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S366/00—Agitating
- Y10S366/02—Micromixers: segmented laminar flow with boundary mixing orthogonal to the direction of fluid propagation with or without geometry influences from the pathway
Definitions
- Microfiuidic analytical systems are being looked to more and more as a viable means for meeting to the desire to increase throughput, decrease costs, improve automation, and improve data quality in the analysis of chemical and biochemical systems.
- the promise of micro fluidics to accomplish many of these goals has been met through the massive parallelization of miniaturized conventional technologies. While providing many benefits over the conventional technologies, the simpler massively parallel systems result in only incremental improvements over conventional technologies, e.g., by a factor of the number of parallel channels.
- these simpler microfiuidic systems do not remove them all. Thus, these systems typically make a minor improvement over conventional systems, e.g., costs, only to run into a further limitation that the microfiuidic system doesn't solve, e.g., concurrent control of parallel systems.
- microfiuidic systems Due to the extremely small dimensions of microfiuidic systems, one generally begins a microfiuidic analysis with substantially less material than in conventional analyses, one often cannot afford to have such a dilution occur. Despite this, it would generally be desirable to provide microfiuidic systems, methods of using these systems and methods of designing these systems, which systems are capable of maximizing throughput by permitting materials to be introduced serially, with a minimum amount of space between them.
- the present invention meets these and a variety of other needs.
- the present invention generally provides methods, devices and systems having optimized throughput rates for serially processed materials in microfiuidic channel systems.
- the present invention provides methods of serially transporting a plurality of test compound plugs in a microfiuidic channel.
- the method comprises providing a first microfiuidic channel having a smallest cross sectional dimension that is less than a maximum dimension d, where:
- a first test compound plug is introduced, followed by an adjacent spacer fluid plug, where P is the period of time used to introduce the test compound plug and the adjacent spacer fluid plug into the channel.
- D is the diffusion coefficient of the test compound in the test compound plug.
- T is an amount of time for the test compound plug to move from introduction into the channel to a point of detection.
- K is a proportionality constant based upon the nature of the channel's cross sectional shape, n is a ratio of initial plug length to average dispersion distance for the test compound in the test compound plug in time T, provided that T is greater than P.
- a second test compound plug is then introduced adjacent to the spacer fluid plug.
- microfiuidic device comprising a body structure which has at least a first microfiuidic channel disposed within it.
- the channel has a smallest cross-sectional dimension of less than d, wherein:
- First and second test compound plugs are disposed in the channel separated by a spacer fluid plug.
- the first test compound plug and spacer fluid plug have a length of L p , n is a ratio of initial plug length to desired dispersion distance of the test compound in the test compound plug, and is between about 0.5 and about 10, D is a diffusion coefficient of the first test compound.
- T is an amount of time for the test compound plug to move from introduction into the channel to a point of detection.
- U is an average linear velocity of the test compound plug through the first microscale channel.
- K is the proportionality constant based upon the nature of the channel's cross-sectional shape.
- a further aspect of the present invention is a method of designing a microfiuidic channel network for performing a serial analysis.
- the method comprises selecting a cycle length of a test plug containing a test compound plug and a spacer plug.
- a diffusion coefficient of the test compound is identified.
- a total reaction time is selected for the test compound.
- One or more of a maximum channel diameter and a channel length for carrying out the analysis is determined, based upon the cycle length, diffusion coefficient and total reaction time.
- the test compound in the test compound plug disperses across less than 50% of the spacer fluid plug during the total reaction time.
- Figure 1 schematically illustrates an example of a microfiuidic system for performing serial analyses on a plurality of sample material/test compound plugs, in cross section.
- Figure 2 schematically illustrates the diffusion/dispersion of sample materials/test compound materials during a particular analysis within a microfiuidic channel of a microfiuidic device.
- Figure 3 schematically illustrates a microfiuidic device and system for performing a plurality of analyses on a library of samples/test compounds that is used in conjunction with the present invention.
- Figure 4 is a graph which illustrates the variation of /(b/a) for laminar flow through a channel of rectangular cross-section.
- Figure 5 A schematically illustrates a cross-section of a rectangular channel
- Figure 5B illustrates a cross-section of an elliptical channel with the major and minor axes labeled appropriately.
- FIGS. 6A-6C schematically illustrates channels which vary in there cross sectional dimensions. DETAILED DESCRIPTION OF THE INVENTION I. General Discussion
- the present invention provides methods of performing high-throughput and even ultra-high-throughput experimentation in microfiuidic devices and systems by minimizing the amount of time required between samples that are serially passing through the channels of the device or system.
- the present invention provides methods of maximizing throughput of serially introduced, but spaced apart fluid samples in microfiuidic channels by providing a microfiuidic channel that meets a number of optimal criteria.
- the microfiuidic systems of sufficiently small cross-sectional dimensions, and by applying fluid manipulation that operates in the laminar flow range one can substantially reduce the level of diffusion, dispersion, and other perturbing effects in microfiuidic channels, and thereby minimize the amount of space between serially introduced materials.
- FIG. 1 schematically illustrates the serial analysis methods and systems of the present invention.
- a microfiuidic device 100 includes a body structure 102, having disposed therein a main analytical channel 104.
- the main analytical channel 104 is typically in fluid communication with sources (not shown) of the various sample materials/test compounds that are to be serially analyzed in the main channel 104.
- communication of the main channel with the sources of sample material is provided through an integrated pipettor element 106 that includes a channel 104a disposed through it, where channel 104a is in fluid communication with the main analytical channel 104.
- reagents for a given analysis are typically flowed along the main channel 104.
- the plurality of sample material/test compound plugs 108 are then serially introduced into the main channel where they interact with the analysis reagents.
- Spacer fluid plugs 110 are introduced into the pipettor channel 104a and analytical channel 104, in order to maintain separation between consecutively introduced test plugs.
- test plugs and interacting reagents are transported along main channel 104 (as shown by the arrows), until they reach a detection point in the channel which is in sensory communication with a detector, e.g., optical detector 118.
- a detector e.g., optical detector 118.
- the present invention provides a method of transporting at least two different fluid regions through a microfiuidic channel whereby dispersion or diffusion of the two fluid regions into each other is minimized.
- this is generally accomplished by providing the microfiuidic channel, which has the dimensions of the channel optimized for throughput and minimal dispersion/diffusion of test plug materials.
- This is generally accomplished by selecting an optimal channel cross-sectional dimension for a given analytical system, e.g., reaction time, diffusion coefficient of test plug materials, desired stringency/resolution of test plugs, and the like.
- dispersion is defined as convection-induced, longitudinal dispersion of material within a fluid medium due to velocity variations across streamlines, e.g., in pressure driven flow systems, electrokmetically driven flow systems around curves and corners, and electrokmetically driven flow systems having non-uniform buffer ionic concentrations, e.g., plugs of high and low salt solutions within the same channel system.
- dispersion is generally defined as that due to the coupling between flow and molecular diffusion, i.e., Taylor dispersion. In this regime, the time-scale for dispersion due to convective transport is long or comparable to the time scale for molecular diffusion in the direction orthogonal to the flow direction.
- T time
- the materials within the test plugs illustrated as circles and squares, diffuse and disperse out of the original test plug volumes, as shown in Figure 2 (Bottom panel).
- the average dispersion distance is illustrated by the dashed lines.
- the original test plug length (L p ⁇ ug ), the period length (L p ) and the linear velocity (U, arrows) are illustrated within the Figure 2, as is the correlation of the desired dispersion distance to n, which is described in greater detail below.
- optimized microfiuidic channels are selected/designed which do not permit excessive diffusion/dispersion, e.g., beyond a desired level of diffusion/dispersion, e.g., as shown by the dashed lines. Identifying the optimal criteria for the microfiuidic channel systems used in accordance with the present invention involves the consideration of many factors.
- test plugs may be introduced into a channel.
- properties of the material such as the diffusion coefficient of the material
- requirements of the application such as the amount of time required between introduction of the sample or test compound material and detection of that material, e.g., to produce a sufficient detectable signal, and the acceptable level of material plug cohesiveness
- structural properties of the microfiuidic channel such as the cross sectional dimensions of the channel.
- the present invention provides methods of producing and using microfiuidic devices and systems, which are optimized for the above-described criteria, while also permitting the optimization of these latter criteria and other influential factors.
- optimizing throughput of a particular serial input system for performing a given assay typically requires serially introducing test plugs as close together as possible, without having excessive intermixing of adjacent test plugs. As a first order, this requires the introduction of spacer fluid plugs between the test plugs, in order to provide the separation between test plugs. As a second order, however, the length of the spacer plug is taken into consideration, and minimized in order to maximize the number of test plugs moved through the system per unit time, while still performing the requisite separation or partitioning function.
- Dispersion of a test plug material is analogous to diffusion of that material.
- dispersion coefficient E is analogous to the diffusion coefficient of the material, and is defined as follows:
- D D where d is the smallest cross sectional dimension of the channel, U is the average linear velocity of material moving through the channel in mm/sec, K is the proportionality factor which is a functional of the channel's cross-sectional shape, and D is the molecular diffusion coefficient of the material or solute.
- x 2DT (2) where T is the amount of time over which diffusion is determined.
- the true area of concern with relation to the systems described herein is the distance that a given molecule moves relative to the length of a combined test/spacer plug, L p . Defining the ratio of the plug length to the diffusion distance as n, one obtains the following equation where:
- d is the upper limit on the diameter of the channel in question, under a particular set of parameters, e.g., test/spacer plug length L p , linear velocity of the material in the channel U, retention time in the channel T, and desired or acceptable dispersion distance n.
- the present invention provides a method of serially transporting fluid plugs that contain sample material or test compound material (referred to herein as "test plugs") through a microfiuidic channel, where those test plugs are separated by plugs of spacer fluid, e.g., buffer.
- test plugs sample material or test compound material
- the microfiuidic channel through which the test plugs are serially transported is provided having its smallest cross-sectional dimension that is less than or equal to about d where: d x. D n 2KT and wherein D is the diffusion coefficient of the sample material or test compound material in the test plug in the fluids present, T is the total retention time of the test plug in the microfiuidic channel, e.g., from introduction of the test plug into the channel to detection of a given result from the test plug at some point along the channel.
- P is less than about 60 seconds
- D is between about 10 " and about 10 " cm /s
- T is greater than 1 second
- n is between about 0.5 and about 20.
- the present invention provides a microfiuidic devices for performing serial high-throughput analyses.
- these devices typically include a body structure that comprises at least a first microfiuidic channel disposed therein. At least one of the channels has a smallest cross-sectional dimension of less than d, wherein:
- first and second test compound plugs disposed in the channel separated by a spacer fluid plug, wherein the first test compound plug and any optionally included spacer fluid plug have a length of L p , n is a ratio of initial plug length to desired dispersion distance of the test compound in the test compound plug, and is between about 0.5 and about 10, D is a diffusion coefficient of the first test compound, K is a proportionality factor, T is an amount of time for the test compound plug to move from introduction into the channel to a point of detection, and U is an average linear velocity of the test compound plug through the first microscale channel.
- L p is less than about 10 mm, preferably less than or equal to about 6 mm
- U is between about 0.05 and about 10 mm/sec and preferably between about 0.2 and 2 mm/sec
- D is between about 10 "5 and about 10 "8 cm 2 Is
- T is greater than about 1 second
- K is greater than about 1/210, and preferably between about 1/210 and 1/24, and
- n is between about 0.5 and about 10.
- channels that are cylindrical, e.g., having a circular cross-sectional shape have a different dispersion profile than for channels that are elliptical, rectangular of finite width or infinite width, i.e. are not limited by the width.
- the proportionality factor K is 1/192.
- the proportionality constant (K) is given by the following equation:
- the proportionality factor is 1/210.
- the proportionality factor is as follows:
- the present invention has been generally described in terms of providing an optimized channel cross-sectional dimension where the other elements of the channel geometry are fungible, e.g., are easily changed.
- other channel dimensions are predetermined for reasons not related to, e.g., throughput.
- throughput it may be necessary to utilize a channel having a sufficiently large cross-sectional dimension to allow sufficient signal acquisition by the detector.
- a channel may require a sufficiently large cross-section to allow particulate materials to pass, e.g., cells, beads or the like, or to slow linear velocity to permit adequate incubation of reactants.
- the necessary cross sectional dimension can be incorporated into the above-described equations, to optimize for throughput based upon that requirement.
- the methods and systems of the present invention are used in the screening of pharmaceutical libraries, e.g., large collections of compounds with potential pharmacological activity.
- library compounds comprise relatively small molecules, e.g., molecular weights less than 10,000 daltons and preferably, less than about 1000 daltons.
- these compounds generally have comparable diffusion coefficients that are less than about 10° and typically between about 10 "5 and 10 " .
- optimization of microfiuidic methods and systems according to the present invention is done for compounds that have diffusion coefficients in the range of from about 10 "5 to about 10 "7 .
- the total retention time (T) for a given test plug may vary depending upon a number of criteria.
- the retention time depends upon the amount of time required for the particular analysis to generate sufficiently detectable signal before the test plug passes in front of the detection portion of the microfiuidic channel. For most fluorogenic assays, this retention time typically varies, but is typically greater than about 1 second, preferably, greater than about 5 seconds, and is often greater than 30 seconds, and in some cases, even greater than 60 seconds. Of course, for extremely fast reactions, retention time may be minimized, or selected simply to optimize the overall processing, e.g., maximizing throughput while permitting sufficient time for the sampling system to pick up the next test plug.
- the throughput of a particular analytical channel depends, in part, on the number of test plugs one can move through the analytical channel per unit time, or how closely together one can introduce such plugs into the channel. Accordingly, the length of the test plug and its accompanying spacer plug is dependent upon the desired throughput level, as well as the necessary size of the test plug, e.g., to ensure the presence of adequate test plug material for analysis. Accordingly, this parameter is typically variable depending upon the investigator's choice. However, in the preferred application of high-throughput pharmaceutical screening, the combined length of the test plug and its adjacent spacer fluid plug (L p ) is from about 0.1 to about 30 mm, and more preferably, from about 1 to about 10 mm.
- the period length (P) for introducing a test plug and its adjacent spacer region is likewise dependent upon the length of the plugs (L p ), as well as the average linear velocity (U) of the plugs being introduced.
- the period length will vary, but will generally be less than about 60 seconds, preferably, less than 30 seconds, optimally, less than 20 seconds, and even more preferably, less than 10 seconds and often less than 5 seconds, while the linear velocity of the fluid in the system typically varies from about 0.05 mm/sec to about 10 mm/sec, and preferably, from about 0.2 mm/sec to about 2 mm/sec.
- the amount of permitted diffusion dispersion is a parameter that is determined in advance by the investigator depending upon the amount of resolution that the investigator desires between test plugs. For example, where one wishes to perform a rough screen of a given library of compounds, one can tolerate far more diffusion/dispersion than if one is performing a highly stringent analysis of a number of critical samples, such as multiple patient sample analyses.
- n would be equal to 5.
- the acceptable average dispersion diffusion in the microfiuidic systems described herein is given by an n value that is greater than 0.5, preferably, greater than or equal 1, and more preferably, greater than or equal to 2 and in many cases, greater than or equal to 4.
- n typically falls between the upper and lower limits described above, e.g., between 0.5 and 20, and preferably, between 1 and 10, 4 and 10, or 1 and 8.
- optimized microfiuidic channels according to the present invention will have a smallest cross-sectional dimension that is less than about 200 ⁇ m, preferably, less than about 100 ⁇ m, and more preferably, less than about 50 ⁇ m, and in many cases, less than about 20 ⁇ m, and even less than about 10 ⁇ m.
- the present invention also provides methods for designing such optimized systems for performing serial analyses.
- these methods comprise selecting a cycle length of a test plug containing a test compound plug and a spacer plug.
- a diffusion coefficient of the test compound is identified.
- a total reaction time is selected for the test compound based upon the desired reaction time as dictated by the nature of the reaction to be carried out.
- One or more of a maximum channel diameter and a channel length for carrying out the analysis is determined, based upon the cycle length, diffusion coefficient and total reaction time, e.g., from the above described equations.
- test compound in the test compound plug has an average dispersion distance of less than 200% of the original test compound plug length, preferably, less than 100%, more preferably, less than 50% and often less than 25% of the original test compound plug length, during the total reaction time.
- Microfiuidic channels, devices and systems incorporating channels having optimized dimensions, as described herein, may incorporate any of number of structural configurations from a simple capillary tube to a more complex planar microfiuidic device incorporating an integrated channel network within its interior region.
- the microfiuidic channels in which the methods described herein are carried out are a portion of an integrated channel network in a microfiuidic device.
- microfiuidic devices may comprise an aggregate of separate parts, e.g., capillary elements, microfabricated chambers, and the like
- microfiuidic devices typically have a layered structure comprised of at least two separate planar substrates that are mated together, whereby the channel network is defined at the interface of the mated substrates, e.g., by being fabricated into a surface of one or both of the planar substrate layers.
- Such devices are described in detail in, e.g., U.S. Patent Application No. 08/845,754, filed April 25, 1997, and incorporated herein by reference for all purposes.
- FIG. 1 An example of a microfiuidic device incorporating such a layered structure is illustrated in Figure 1, where the main body structure 102 of the device 100 is comprised of at least two separate substrate layers 114 and 116, which are mated together to define the channel portion, e.g., channel 104, of the device 100.
- Substrates for use in fabricating the devices described herein are typically selected based upon their ease of micro fabrication, as well as their compatibility with the conditions to which they will be subjected, e.g., extremes of salt concentration, pH, pressure, temperature, and the like.
- silica based substrates are preferred because of their amenability to microfabrication using, e.g., photolithographic fabrication techniques, and their general inertness to reaction/analysis conditions.
- polymeric substrates which provide advantages of cost and ease of fabrication over silica-based substrates using, e.g., injection molding, embossing, stamping or other fabrication methods whereby large numbers of inexpensive disposable devices may be fabricated at a time. Examples of preferred polymeric materials and methods for fabricating microfiuidic devices from these materials are described in, e.g., U.S. Patent Application No. 08/ 843,212, filed April 14, 1997, and incorporated herein by reference in its entirety for all purposes.
- FIG. 3 A and 3B An example of a preferred overall microfiuidic system 300 for use in carrying out high-throughput serial analyses is shown in Figures 3 A and 3B.
- a microfiuidic device 302 is provided having at least a first analytical channel 304 disposed within its interior region and which terminates at one end in a waste reservoir 306.
- the channel is fluidly connected to reagent sources 308-314 via channels 316-322, respectively.
- the analytical channel is also fluidly connected to a pipettor channel 304a disposed in pipettor element 324.
- test plugs and spacer fluid plugs are sipped into channels 304a and 304 by contacting the open end of the pipettor element 324 with the test compound sources and spacer fluid source, e.g., disposed in the wells 330 of multiwell plate 332.
- the test plugs, and their effect on the analysis are then detected in analytical channel 104, e.g., by detector 334
- Sipping the test fluid plugs and spacer fluid plugs into the analytical channel from the multiwell plates, as well as movement of the fluid reagents, test plugs and spacer plugs through the channels of the device shown in Figure 3, is carried out by any of a number of methods.
- fluid movement is carried out through the application of pressure differentials through which fluid flow is desired. This is optionally achieved by applying vacuum, e.g., negative pressures, or positive pressures to one or more of the reservoirs/ports at the termini of the various channels of the device, to controllably drive fluids through the channels. Controlled application of pressure differentials through different, intersecting channel segments allows one to control the ratio of material moving through each of the channel segments.
- fluid transport may be provided using electrokinetic systems that move fluids and other materials through the application of electric fields along the length of those channels.
- the application of electric fields across channel lengths is typically achieved through electrodes placed into contact with fluids disposed in the reservoirs/ports at the various channel termini, which electrodes are coupled to an appropriate electrical controller that delivers the requisite voltages to the electrodes.
- electrokinetic fluid transport systems By using controlled electrokinetic fluid transport systems, one can effectively control the flow and direction of fluids and other materials within the microfiuidic device without the need for mechanical pumping and valving structures. Controlled electrokinetic transport is described in detail in, e.g., Published International Patent Application No. 96/04547, to Ramsey et al., which is incorporated herein by reference for all purposes.
- Some exemplary analyses were set up in order to illustrate the performance of the optimization methods of the present invention.
- the following table illustrates a number of different criteria for different analyses, and the determination of the optimized channel cross- sectional dimension for carrying out the analysis based upon the different criteria.
- the optimized microfiuidic channels, devices and systems of the invention are generally useful in performing high-throughput, and even ultra high- throughput serial analyses.
- Particularly preferred high-throughput analyses include screening large numbers of pharmaceutical library compounds for effects on biochemical systems, screening large numbers of patient samples, e.g., for clinical analysis, and the like.
- a microfiuidic channel is provided through which at least a first component of a biochemical system is flowed, typically in a continuous stream.
- a biochemical system generally refers to a chemical interaction between molecules of the type generally found within living organisms. Such interactions include the full range of catabolic and anabolic reactions which occur in living systems including enzymatic, binding, signaling and other reactions.
- biochemical systems will also include model systems which are mimetic of a particular biochemical interaction.
- biochemical systems of particular interest in practicing the present invention include, e.g., receptor-ligand interactions, enzyme-substrate interactions, cellular signaling pathways, transport reactions involving model barrier systems (e.g., cells or membrane fractions) for bioavailability screening, and a variety of other general systems.
- model barrier systems e.g., cells or membrane fractions
- Cellular or organismal viability or activity may also be screened using the methods and apparatuses of the present invention, i.e., in toxicology studies.
- the present invention In order to provide methods and devices for screening compounds for effects on biochemical systems, the present invention generally incorporates model in vitro systems which mimic a given biochemical system in vivo for which affector compounds are desired.
- test compounds may be screened for their ability to block systems that are responsible, at least in part, for the onset of disease or for the occurrence of particular symptoms of diseases, including, e.g., hereditary diseases, cancer, bacterial or viral infections and the like. Compounds which show promising results in these screening assay methods are then optionally subjected to further testing to identify effective pharmacological agents for the treatment of disease or symptoms of a disease.
- compounds can be screened for their ability to stimulate, enhance or otherwise induce biochemical systems whose function is believed to be desirable, e.g., to remedy existing deficiencies in a patient.
- the biochemical system models employed in the methods and apparatuses of the present invention will screen for an effect of a test compound on an interaction between two components of a biochemical system, e.g., receptor-ligand interaction, enzyme-substrate interaction, and the like.
- the biochemical system model will typically include the two normally interacting components of the system for which an affector is sought, e.g., the receptor and its ligand or the enzyme and its substrate.
- Determining whether a test compound has an effect on this interaction then involves contacting the system with the test compound and assaying for the functioning of the system, e.g., receptor-ligand binding or substrate turnover.
- the assayed function is then compared to a control, e.g., the same reaction in the absence of the test compound or in the presence of a known affector.
- a control e.g., the same reaction in the absence of the test compound or in the presence of a known affector.
- the methods and apparatuses may also be used to screen for affectors of much more complex systems where the result or end product of the system is known and assayable at some level, e.g., enzymatic pathways, cell signaling pathways and the like.
- the methods and apparatuses described herein may be used to screen for compounds that interact with a single component of a biochemical system, e.g., compounds that specifically bind to a particular biochemical compound, e.g., a receptor, ligand, enzyme, nucleic acid, structural macromolecule, etc.
- a biochemical system e.g., compounds that specifically bind to a particular biochemical compound, e.g., a receptor, ligand, enzyme, nucleic acid, structural macromolecule, etc.
- Biochemical system models may also be embodied in whole cell systems. For example, where one is seeking to screen test compounds for an effect on a cellular response, whole cells may be utilized.
- Some general examples of cellular functions/responses that are of particular interest in pharmaceutical research include transport functions, i.e., ion channel activation, binding functions, i.e., ligand/receptor binding, nucleic acid hybridization, expression functions, i.e., gene expression and protein translocation, and overall cellular viability.
- Transport functions i.e., ion channel activation
- binding functions i.e., ligand/receptor binding
- nucleic acid hybridization i.e., gene expression and protein translocation
- expression functions i.e., gene expression and protein translocation
- overall cellular viability i.e., gene expression and protein translocation
- chimeric reporter systems may be employed as indicators of an effect of a test compound on a particular biochemical system.
- Chimeric reporter systems typically incorporate a heterogenous reporter system integrated into a signaling pathway which signals the binding of a receptor to its ligand.
- a receptor may be fused to a heterologous protein, e.g., an enzyme whose activity is readily assayable. Activation of the receptor by ligand binding then activates the heterologous protein which then allows for detection.
- the surrogate reporter system produces an event or signal which is readily detectable, thereby providing an assay for receptor/ligand binding. Examples of such chimeric reporter systems have been previously described in the art.
- biological barriers generally refers to cellular or membranous layers within biological systems, or synthetic models thereof. Examples of such biological barriers include the epithelial and endothelial layers, e.g. vascular endothelia and the like.
- biological barriers In the case of cell-based screening operations therefore, a stream of a suspension of cells is transported along the main microfiuidic channel to be contacted with the test compound plugs introduced therein.
- Biological responses are often triggered and/or controlled by the binding of a receptor to its ligand.
- interaction of growth factors i.e., EGF, FGF, PDGF, etc.
- EGF e.g., EGF, FGF, PDGF, etc.
- their receptors stimulate a wide variety of biological responses including, e.g., cell proliferation and differentiation, activation of mediating enzymes, stimulation of messenger turnover, alterations in ion fluxes, activation of enzymes, changes in cell shape and the alteration in genetic expression levels.
- control of the interaction of the receptor and its ligand may offer control of the biological responses caused by that interaction.
- the present invention is useful in screening for compounds that affect an interaction between a receptor molecule and its ligands.
- the term "receptor” generally refers to one member of a pair of compounds, which specifically recognize and bind to each other. The other member of the pair is termed a "ligand.”
- a receptor/ligand pair may include a typical protein receptor, usually membrane associated, and its natural ligand, e.g., another protein or small molecule.
- Receptor/ligand pairs may also include antibody/antigen binding pairs, complementary nucleic acids, nucleic acid associating proteins and their nucleic acid ligands.
- a large number of specifically associating biochemical compounds are well known in the art and can be utilized in practicing the present invention.
- test compound is determined to be an inhibitor of the receptor/ligand binding.
- enhancer or inducer of the interaction is determined to be an enhancer or inducer of the interaction.
- a similar, and perhaps overlapping, set of biochemical systems includes the interactions between enzymes and their substrates.
- enzyme as used herein, generally refers to a protein which acts as a catalyst to induce a chemical change in other compounds or "substrates.”
- affectors of an enzyme's activity toward its substrate are screened by contacting the enzyme with a substrate in the presence and absence of the compound to be screened and under conditions optimal for detecting changes in the enzyme's activity. After a set time for reaction, the mixture is assayed for the presence of reaction products or a decrease in the amount of substrate. The amount of substrate that has been catalyzed is then compared to a control, i.e., enzyme contacted with substrate in the absence of test compound or presence of a known effector.
- a control i.e., enzyme contacted with substrate in the absence of test compound or presence of a known effector.
- the various screening methods encompassed by the present invention involve the serial introduction of a plurality of test compounds into a microfiuidic device. Once injected into the device, the test compound may be screened for effect on a biological system using a continuous serial or parallel assay orientation.
- test compound refers to the collection of compounds that are to be screened for their ability to affect a particular biochemical system.
- Test compounds may include a wide variety of different compounds, including chemical compounds, mixtures of chemical compounds, e.g., polysaccharides, small organic or inorganic molecules, biological macromolecules, e.g., peptides, proteins, nucleic acids, or an extract made from biological materials such as bacteria, plants, fungi, or animal cells or tissues, naturally occurring or synthetic compositions.
- the test compounds may be provided, e.g., injected, free in solution, or may be attached to a carrier, or a solid support, e.g., beads.
- suitable solid supports may be employed for immobilization of the test compounds.
- suitable solid supports include agarose, cellulose, dextran (commercially available as, i.e., Sephadex, Sepharose) carboxymethyl cellulose, polystyrene, polyethylene glycol (PEG), filter paper, nitrocellulose, ion exchange resins, plastic films, glass beads, polyaminemethylvinylether maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc.
- test compounds may be screened individually, or in groups. Group screening is particularly useful where hit rates for effective test compounds are expected to be low such that one would not expect more than one positive result for a given group.
- the functioning of the system is indicated by the production of a detectable event or signal.
- detectable signals will include chromophoric or fluorescent signals that are associated with the functioning of the particular model biochemical system used.
- signals will generally be produced by products of the enzyme's catalytic action, e.g., on a chromogenic or fluorogenic substrate.
- binding systems e.g., receptor ligand interactions, signals will typically involve the association of a labeled ligand with the receptor, or vice versa, or changes that the association imparts on the signal, quantitatively or temporally.
- the continuous system generates a constant signal which varies only when a test compound is introduced that affects the system. Specifically, as the system components flow along the channel, they will produce a relatively constant signal level at a detection zone or window of the channel. Test compounds are periodically introduced into the channel and mixed with the system components. Where those test compounds have an effect on the system, it will cause a deviation from the constant signal level at the detection window. This deviation may then be correlated to the particular test compound screened.
- the substrate may be a chromogenic or fluorogenic substrate which produces an optically detectable signal when the enzyme acts upon the substrate.
- the first component is a receptor and the second is a ligand
- either the ligand or the receptor may bear a detectable signal.
- the mixture and flow rate of compounds will typically remain constant such that the flow of the mixture of the first and second components past the detection window 116 will produce a steady-state signal.
- steady state signal is generally meant a signal that has a regular, predictable signal intensity profile.
- the steady-state signal may include signals having a constant signal intensity, or alternatively, a signal with a regular periodic intensity, against which variations in the normal signal profile may be measured.
- This latter signal may be generated in cases where fluid flow is periodically interrupted for, e.g., loading additional test compounds, as described in the description of the continuous flow systems.
- the signal produced in the above- described enzymatic system will vary along the length of the channel, i.e., increasing with time of exposure as the enzyme converts the fluorogenic substrate to the fluorescent product, the signal at any specific point along the channel will remain constant, given a constant flow rate.
- the receptor and its fluorescent ligand can be made to have different flow rates along the channel. This can be accomplished by incorporating size exclusion matrices within the channel, or, in the case of electroosmotic methods, altering the relative electrophoretic mobility of the two compounds so that the receptor flows more rapidly down the channel. Again, this may be accomplished through the use of size exclusion matrices, or through the use of different surface charges in the channel which will result in differential flow rates of charge-varied compounds. Where a test compound binds to the receptor, it will result in a dark pulse in the fluorescent signal followed by a brighter pulse.
- the steady state signal is a result of both free fluorescent ligand, and fluorescent ligand bound to the receptor.
- the bound ligand is traveling at the same flow rate as the receptor while the unbound ligand is traveling more slowly.
- the receptor will not 'bring along' the fluorescent ligand, thereby diluting the fluorescent ligand in the direction of flow, and leaving an excess of free fluorescent ligand behind. This results in a temporary reduction in the steady-state signal, followed by a temporary increase in fluorescence.
- schemes similar to those employed for the enzymatic system may be employed, where there is a signal that reflects the interaction of the receptor with its ligand.
- pH indicators which indicate pH effects of receptor-ligand binding may be incorporated into the device along with the biochemical system, i.e., in the form of encapsulated cells, whereby slight pH changes resulting from binding can be detected. See Weaver, et al., Bio/Technology (1988) 6:1084-1089. Additionally, one can monitor activation of enzymes resulting from receptor ligand binding, e.g., activation of kinases, or detect conformational changes in such enzymes upon activation, e.g., through incorporation of a fluorophore which is activated or quenched by the conformational change to the enzyme upon activation.
- assay and channel parameters were predetermined and/or preordained based upon the assay that was to be performed in the device to be performed, e.g., buffer/analyte properties and incubation time, as well as practicalities of the microfiuidic device structure, e.g., channel and capillary dimensions.
- incubation time is generally dictated by the kinetics of the assay that is to be performed. This, in turn, dictates the amount of time that a reaction mixture remains in the reaction channel, which is a function of flow rate and channel length.
- channel depth can be dictated by the detection limits of the system used to detect signals within the channels, e.g., so as to permit the presence of adequate levels of signal at the detection zone.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU28533/00A AU767342B2 (en) | 1999-01-19 | 2000-01-18 | Optimized high-throughput analytical system |
CA002360013A CA2360013A1 (en) | 1999-01-19 | 2000-01-18 | Optimized high-throughput analytical system |
EP00906956A EP1144674A4 (en) | 1999-01-19 | 2000-01-18 | Optimized high-throughput analytical system |
JP2000593769A JP2002534700A (en) | 1999-01-19 | 2000-01-18 | Optimal high-throughput analysis system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/233,700 US6150119A (en) | 1999-01-19 | 1999-01-19 | Optimized high-throughput analytical system |
US09/233,700 | 1999-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000042212A1 true WO2000042212A1 (en) | 2000-07-20 |
Family
ID=22878350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001268 WO2000042212A1 (en) | 1999-01-19 | 2000-01-18 | Optimized high-throughput analytical system |
Country Status (6)
Country | Link |
---|---|
US (2) | US6150119A (en) |
EP (1) | EP1144674A4 (en) |
JP (1) | JP2002534700A (en) |
AU (1) | AU767342B2 (en) |
CA (1) | CA2360013A1 (en) |
WO (1) | WO2000042212A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508837A (en) * | 2000-09-14 | 2004-03-25 | カリパー・テクノロジーズ・コープ. | Microfluidic device and method for performing temperature-mediated reactions |
EP3677336A1 (en) | 2007-09-05 | 2020-07-08 | Caliper Life Sciences Inc. | Microfluidic method and system for enzyme inhibition activity screening |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048734A (en) | 1995-09-15 | 2000-04-11 | The Regents Of The University Of Michigan | Thermal microvalves in a fluid flow method |
CA2279574C (en) | 1997-01-31 | 2007-07-24 | The Horticulture & Food Research Institute Of New Zealand Ltd. | Optical apparatus |
US6149867A (en) | 1997-12-31 | 2000-11-21 | Xy, Inc. | Sheath fluids and collection systems for sex-specific cytometer sorting of sperm |
US6071689A (en) * | 1997-12-31 | 2000-06-06 | Xy, Inc. | System for improving yield of sexed embryos in mammals |
US6348354B1 (en) * | 1998-07-06 | 2002-02-19 | Bayer Corporation | Method and apparatus for controlling a stream of liquid test packages in a capsule chemistry analysis system |
US20020019059A1 (en) * | 1999-01-28 | 2002-02-14 | Calvin Y.H. Chow | Devices, systems and methods for time domain multiplexing of reagents |
WO2000070080A1 (en) * | 1999-05-17 | 2000-11-23 | Caliper Technologies Corp. | Focusing of microparticles in microfluidic systems |
US6524456B1 (en) * | 1999-08-12 | 2003-02-25 | Ut-Battelle, Llc | Microfluidic devices for the controlled manipulation of small volumes |
US20020139668A1 (en) * | 1999-11-03 | 2002-10-03 | Raghbir Singh Bhullar | Embedded metallic deposits |
US6875619B2 (en) * | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
US6361958B1 (en) | 1999-11-12 | 2002-03-26 | Motorola, Inc. | Biochannel assay for hybridization with biomaterial |
US7208265B1 (en) * | 1999-11-24 | 2007-04-24 | Xy, Inc. | Method of cryopreserving selected sperm cells |
EP1275005A1 (en) * | 2000-04-06 | 2003-01-15 | Caliper Technologies Corporation | Methods and devices for achieving long incubation times in high-throughput systems |
US20040031071A1 (en) * | 2000-10-05 | 2004-02-12 | Xy, Inc. | System of hysteroscopic insemination of mares |
US6902938B1 (en) * | 2000-10-10 | 2005-06-07 | Jeol Usa, Inc. | Chemical analysis method for multiplexed samples |
US7378280B2 (en) * | 2000-11-16 | 2008-05-27 | California Institute Of Technology | Apparatus and methods for conducting assays and high throughput screening |
US7713687B2 (en) * | 2000-11-29 | 2010-05-11 | Xy, Inc. | System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations |
CA2468772C (en) * | 2000-11-29 | 2013-10-29 | George E. Seidel | System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations |
US20020108860A1 (en) * | 2001-01-15 | 2002-08-15 | Staats Sau Lan Tang | Fabrication of polymeric microfluidic devices |
GB0103441D0 (en) * | 2001-02-13 | 2001-03-28 | Secr Defence | Microchannel device |
TW593122B (en) * | 2001-02-13 | 2004-06-21 | Qinetiq Ltd | Microchannel device |
US6692700B2 (en) | 2001-02-14 | 2004-02-17 | Handylab, Inc. | Heat-reduction methods and systems related to microfluidic devices |
US6852287B2 (en) | 2001-09-12 | 2005-02-08 | Handylab, Inc. | Microfluidic devices having a reduced number of input and output connections |
US7829025B2 (en) | 2001-03-28 | 2010-11-09 | Venture Lending & Leasing Iv, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US7323140B2 (en) | 2001-03-28 | 2008-01-29 | Handylab, Inc. | Moving microdroplets in a microfluidic device |
US8895311B1 (en) | 2001-03-28 | 2014-11-25 | Handylab, Inc. | Methods and systems for control of general purpose microfluidic devices |
US7010391B2 (en) | 2001-03-28 | 2006-03-07 | Handylab, Inc. | Methods and systems for control of microfluidic devices |
EP1384022A4 (en) | 2001-04-06 | 2004-08-04 | California Inst Of Techn | Nucleic acid amplification utilizing microfluidic devices |
JP3920221B2 (en) * | 2001-05-02 | 2007-05-30 | アプレラ コーポレイション | Concentration and purification of analytes using electric fields |
US7179423B2 (en) | 2001-06-20 | 2007-02-20 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US20030015425A1 (en) * | 2001-06-20 | 2003-01-23 | Coventor Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US7211442B2 (en) * | 2001-06-20 | 2007-05-01 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US20020197733A1 (en) * | 2001-06-20 | 2002-12-26 | Coventor, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US20030077570A1 (en) * | 2001-09-20 | 2003-04-24 | Coventor, Inc. | Small molecule substrate based enzyme activity assays |
WO2003000418A2 (en) * | 2001-06-20 | 2003-01-03 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US6825127B2 (en) | 2001-07-24 | 2004-11-30 | Zarlink Semiconductor Inc. | Micro-fluidic devices |
US20060062696A1 (en) * | 2001-07-27 | 2006-03-23 | Caliper Life Sciences, Inc. | Optimized high throughput analytical systems |
WO2003048295A1 (en) | 2001-11-30 | 2003-06-12 | Fluidigm Corporation | Microfluidic device and methods of using same |
US7459127B2 (en) | 2002-02-26 | 2008-12-02 | Siemens Healthcare Diagnostics Inc. | Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces |
CA2480728A1 (en) | 2002-04-01 | 2003-10-16 | Fluidigm Corporation | Microfluidic particle-analysis systems |
WO2003084629A2 (en) | 2002-04-02 | 2003-10-16 | Caliper Life Sciences, Inc. | Methods and apparatus for separation and isolation of components from a biological sample |
US7488309B2 (en) * | 2002-07-03 | 2009-02-10 | Bioanalytical Systems, Inc. | Device and method for drug delivery to animals |
BR0312843A (en) * | 2002-07-22 | 2005-05-10 | Xy Inc | System to process sperm cells |
US8486618B2 (en) | 2002-08-01 | 2013-07-16 | Xy, Llc | Heterogeneous inseminate system |
NZ538462A (en) * | 2002-08-01 | 2008-06-30 | Xy Inc | Low pressure sperm cell separation system |
US20040053315A1 (en) * | 2002-08-12 | 2004-03-18 | Caliper Technologies Corp. | Methods and systems for monitoring molecular interactions |
AU2006235974B2 (en) * | 2002-08-12 | 2007-11-15 | Caliper Life Sciences, Inc. | Methods and systems for monitoring molecular interactions |
US7855078B2 (en) * | 2002-08-15 | 2010-12-21 | Xy, Llc | High resolution flow cytometer |
BR0313618A (en) | 2002-08-21 | 2005-06-21 | Shell Int Research | Method for chemical analysis of well fluids |
US7169548B2 (en) | 2002-09-13 | 2007-01-30 | Xy, Inc. | Sperm cell processing and preservation systems |
EP1551753A2 (en) | 2002-09-25 | 2005-07-13 | California Institute Of Technology | Microfluidic large scale integration |
EP1569510B1 (en) | 2002-09-27 | 2011-11-02 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
JP5695287B2 (en) | 2002-10-02 | 2015-04-01 | カリフォルニア インスティテュート オブ テクノロジー | Nucleic acid analysis of microfluids |
JP2006521116A (en) | 2003-03-27 | 2006-09-21 | ピーティーシー セラピューティクス,インコーポレーテッド | Targeting enzymes in the tRNA splicing pathway to identify antifungal and / or antiproliferative molecules |
EP2308416B1 (en) | 2003-03-28 | 2015-01-07 | Inguran, LLC | Apparatus and methods for providing sex-sorted animal sperm |
US7147764B2 (en) * | 2003-03-28 | 2006-12-12 | Applera Corporation | Dual electrode injection of analyte into a capillary electrophoretic device |
US7604965B2 (en) | 2003-04-03 | 2009-10-20 | Fluidigm Corporation | Thermal reaction device and method for using the same |
AU2004242121B2 (en) * | 2003-05-15 | 2010-06-24 | Xy, Llc. | Efficient haploid cell sorting for flow cytometer systems |
US7435381B2 (en) | 2003-05-29 | 2008-10-14 | Siemens Healthcare Diagnostics Inc. | Packaging of microfluidic devices |
US8043846B2 (en) * | 2003-06-13 | 2011-10-25 | The General Hospital Corporation | Device and method for contacting picoliter volumes of fluid |
EP2402089A1 (en) | 2003-07-31 | 2012-01-04 | Handylab, Inc. | Processing particle-containing samples |
US7767435B2 (en) * | 2003-08-25 | 2010-08-03 | University Of Washington | Method and device for biochemical detection and analysis of subcellular compartments from a single cell |
US20060057597A1 (en) * | 2003-11-12 | 2006-03-16 | California Institute Of Technology | Method and system for processing nanoparticles using a self assembly mechanism to form combined species |
US7892725B2 (en) | 2004-03-29 | 2011-02-22 | Inguran, Llc | Process for storing a sperm dispersion |
US8852862B2 (en) | 2004-05-03 | 2014-10-07 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
EP2345739B8 (en) * | 2004-05-03 | 2016-12-07 | Handylab, Inc. | A microfluidic device for processing polynucleotide-containing samples |
AR049732A1 (en) | 2004-07-22 | 2006-08-30 | Monsanto Co | PROCESS TO ENRICH A Sperm Cell Population |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
JP2009511059A (en) * | 2005-10-11 | 2009-03-19 | ハンディーラブ インコーポレイテッド | Polynucleotide sample preparation device |
US8172455B2 (en) * | 2005-10-28 | 2012-05-08 | Arkray, Inc. | Liquid feeding method and cartridge to be used therein |
US7815868B1 (en) | 2006-02-28 | 2010-10-19 | Fluidigm Corporation | Microfluidic reaction apparatus for high throughput screening |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US7998708B2 (en) * | 2006-03-24 | 2011-08-16 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
EP2001990B1 (en) | 2006-03-24 | 2016-06-29 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using same |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
KR100758274B1 (en) | 2006-09-27 | 2007-09-12 | 한국전자통신연구원 | Microfluidic device for equalizing multiple microfluids in a chamber, and microfluidic network using it |
WO2008060604A2 (en) | 2006-11-14 | 2008-05-22 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
EP2091647A2 (en) * | 2006-11-14 | 2009-08-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US8101426B2 (en) * | 2007-03-02 | 2012-01-24 | Icyt Mission Technology, Inc. | System and method for the measurement of multiple fluorescence emissions in a flow cytometry system |
US7799656B2 (en) | 2007-03-15 | 2010-09-21 | Dalsa Semiconductor Inc. | Microchannels for BioMEMS devices |
US8182763B2 (en) | 2007-07-13 | 2012-05-22 | Handylab, Inc. | Rack for sample tubes and reagent holders |
US20090136385A1 (en) | 2007-07-13 | 2009-05-28 | Handylab, Inc. | Reagent Tube |
US9618139B2 (en) | 2007-07-13 | 2017-04-11 | Handylab, Inc. | Integrated heater and magnetic separator |
US8133671B2 (en) | 2007-07-13 | 2012-03-13 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US9186677B2 (en) | 2007-07-13 | 2015-11-17 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US8287820B2 (en) | 2007-07-13 | 2012-10-16 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
USD621060S1 (en) | 2008-07-14 | 2010-08-03 | Handylab, Inc. | Microfluidic cartridge |
EP3741869A1 (en) | 2007-07-13 | 2020-11-25 | Handylab, Inc. | Polynucleotide capture materials and methods of using same |
US8105783B2 (en) | 2007-07-13 | 2012-01-31 | Handylab, Inc. | Microfluidic cartridge |
US8016260B2 (en) | 2007-07-19 | 2011-09-13 | Formulatrix, Inc. | Metering assembly and method of dispensing fluid |
USD618820S1 (en) | 2008-07-11 | 2010-06-29 | Handylab, Inc. | Reagent holder |
USD787087S1 (en) | 2008-07-14 | 2017-05-16 | Handylab, Inc. | Housing |
US7927904B2 (en) | 2009-01-05 | 2011-04-19 | Dalsa Semiconductor Inc. | Method of making BIOMEMS devices |
US8100293B2 (en) | 2009-01-23 | 2012-01-24 | Formulatrix, Inc. | Microfluidic dispensing assembly |
ES2769028T3 (en) | 2011-04-15 | 2020-06-24 | Becton Dickinson Co | Real-time scanning microfluidic thermocycler |
WO2013040428A1 (en) * | 2011-09-14 | 2013-03-21 | Dcb-Usa Llc | Microfluidic chips for acquiring sperms with high motility, productions and applications thereof |
USD692162S1 (en) | 2011-09-30 | 2013-10-22 | Becton, Dickinson And Company | Single piece reagent holder |
CA2849917C (en) | 2011-09-30 | 2020-03-31 | Becton, Dickinson And Company | Unitized reagent strip |
EP2773892B1 (en) | 2011-11-04 | 2020-10-07 | Handylab, Inc. | Polynucleotide sample preparation device |
RU2658773C2 (en) | 2012-02-03 | 2018-06-22 | Бектон, Дикинсон Энд Компани | System and method of implementation of automated assays on plurality of biological samples |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304487A (en) * | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5585069A (en) * | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
US5942443A (en) * | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
US5957579A (en) * | 1997-10-09 | 1999-09-28 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4390403A (en) * | 1981-07-24 | 1983-06-28 | Batchelder J Samuel | Method and apparatus for dielectrophoretic manipulation of chemical species |
US4908112A (en) * | 1988-06-16 | 1990-03-13 | E. I. Du Pont De Nemours & Co. | Silicon semiconductor wafer for analyzing micronic biological samples |
US5126022A (en) * | 1990-02-28 | 1992-06-30 | Soane Tecnologies, Inc. | Method and device for moving molecules by the application of a plurality of electrical fields |
US5750015A (en) | 1990-02-28 | 1998-05-12 | Soane Biosciences | Method and device for moving molecules by the application of a plurality of electrical fields |
DE59108006D1 (en) * | 1991-01-28 | 1996-08-22 | Ciba Geigy Ag | Device for the preparation of samples, in particular for analysis purposes |
MX9204374A (en) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
US5637469A (en) * | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
DE59410283D1 (en) * | 1993-11-11 | 2003-06-18 | Aclara Biosciences Inc | Device and method for the electrophoretic separation of fluid substance mixtures |
US6001229A (en) * | 1994-08-01 | 1999-12-14 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing microfluidic manipulations for chemical analysis |
US5571410A (en) * | 1994-10-19 | 1996-11-05 | Hewlett Packard Company | Fully integrated miniaturized planar liquid sample handling and analysis device |
CN1087960C (en) * | 1994-10-22 | 2002-07-24 | 研究中心实验室(有限) | Method and apparatus for diffusive transfer between immiscible fluids |
US5603351A (en) * | 1995-06-07 | 1997-02-18 | David Sarnoff Research Center, Inc. | Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device |
WO1997000442A1 (en) * | 1995-06-16 | 1997-01-03 | The University Of Washington | Microfabricated differential extraction device and method |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5779868A (en) * | 1996-06-28 | 1998-07-14 | Caliper Technologies Corporation | Electropipettor and compensation means for electrophoretic bias |
BR9710054A (en) * | 1996-06-28 | 2000-01-11 | Caliper Techn Corp | Apparatus for separating test compounds for an effect on a biochemical system and for detecting a effect of a test compound on a biochemical system, procedures for determining whether a sample contains a compound capable of affecting a biochemical system, for separating a plurality of test compounds for an effect on a biochemical system and uses of a microfluidic system and a test substrate. |
AU726987B2 (en) * | 1996-06-28 | 2000-11-30 | Caliper Life Sciences, Inc. | Electropipettor and compensation means for electrophoretic bias |
US5800690A (en) * | 1996-07-03 | 1998-09-01 | Caliper Technologies Corporation | Variable control of electroosmotic and/or electrophoretic forces within a fluid-containing structure via electrical forces |
US5699157A (en) * | 1996-07-16 | 1997-12-16 | Caliper Technologies Corp. | Fourier detection of species migrating in a microchannel |
US5869004A (en) * | 1997-06-09 | 1999-02-09 | Caliper Technologies Corp. | Methods and apparatus for in situ concentration and/or dilution of materials in microfluidic systems |
US5882465A (en) * | 1997-06-18 | 1999-03-16 | Caliper Technologies Corp. | Method of manufacturing microfluidic devices |
US5876675A (en) * | 1997-08-05 | 1999-03-02 | Caliper Technologies Corp. | Microfluidic devices and systems |
-
1999
- 1999-01-19 US US09/233,700 patent/US6150119A/en not_active Expired - Fee Related
-
2000
- 2000-01-18 WO PCT/US2000/001268 patent/WO2000042212A1/en not_active Application Discontinuation
- 2000-01-18 CA CA002360013A patent/CA2360013A1/en not_active Abandoned
- 2000-01-18 JP JP2000593769A patent/JP2002534700A/en active Pending
- 2000-01-18 AU AU28533/00A patent/AU767342B2/en not_active Ceased
- 2000-01-18 EP EP00906956A patent/EP1144674A4/en not_active Withdrawn
- 2000-08-02 US US09/630,866 patent/US6511853B1/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304487A (en) * | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5585069A (en) * | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
US5942443A (en) * | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
US5957579A (en) * | 1997-10-09 | 1999-09-28 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
Non-Patent Citations (7)
Title |
---|
EFFENHAUSER ET AL.: "Glass chips for high-speed capillary electrophoresis separations with submicrometer plate heights", ANAL. CHEM.,, vol. 65, no. 19, October 1993 (1993-10-01), pages 2637 - 2642, XP002926773 * |
JACOBSON ET AL.: "Fused quartz substrates for microchip electrophoresis", ANAL. CHEM.,, vol. 67, no. 13, July 1995 (1995-07-01), pages 2059 - 2063, XP002926770 * |
JACOBSON ET AL.: "High-speed separations of a microchip", ANAL. CHEM.,, vol. 66, no. 7, April 1994 (1994-04-01), pages 1114 - 1118, XP002926771 * |
JACOBSON ET AL.: "Microchip electrophoresis with sample stacking", ELECTROPHORESIS,, vol. 16, 1995, pages 481 - 486, XP002926775 * |
MANZ ET AL.: "Miniaturized total chemical analysis systems: a novel concept for chemical sensing", SENSORS AND ACTUATORS,, vol. B1, 1990, pages 244 - 248, XP002926772 * |
See also references of EP1144674A4 * |
SEILER ET AL.: "Planar glass chips for capillary electrophoresis: Repetitive sample injection, quantitation and separation efficiency", ANAL. CHEM.,, vol. 65, no. 10, May 1993 (1993-05-01), pages 1481 - 1488, XP002926774 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508837A (en) * | 2000-09-14 | 2004-03-25 | カリパー・テクノロジーズ・コープ. | Microfluidic device and method for performing temperature-mediated reactions |
EP3677336A1 (en) | 2007-09-05 | 2020-07-08 | Caliper Life Sciences Inc. | Microfluidic method and system for enzyme inhibition activity screening |
Also Published As
Publication number | Publication date |
---|---|
CA2360013A1 (en) | 2000-07-20 |
EP1144674A1 (en) | 2001-10-17 |
US6150119A (en) | 2000-11-21 |
EP1144674A4 (en) | 2005-07-27 |
US6511853B1 (en) | 2003-01-28 |
AU767342B2 (en) | 2003-11-06 |
JP2002534700A (en) | 2002-10-15 |
AU2853300A (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6150119A (en) | Optimized high-throughput analytical system | |
US5942443A (en) | High throughput screening assay systems in microscale fluidic devices | |
US6551836B1 (en) | Microfluidic devices, systems and methods for performing integrated reactions and separations | |
AU2003258116B2 (en) | Methods and systems for monitoring molecular interactions | |
Krishnan et al. | Microfabricated reaction and separation systems | |
Bange et al. | Microfluidic immunosensor systems | |
DE69634490T2 (en) | APPARATUS AND METHOD FOR MOVING FLUIDS BY CENTRIFUGAL ACCELERATION IN AUTOMATIC LABORATORY TREATMENT | |
JP3989964B2 (en) | Integrated microfluidic device | |
US6274089B1 (en) | Microfluidic devices, systems and methods for performing integrated reactions and separations | |
US20070017812A1 (en) | Optimized Sample Injection Structures in Microfluidic Separations | |
EP1710562A2 (en) | Microfluidic system and method of utilization | |
CN100360940C (en) | Method and apparatus for screening G protein coupled receptor medicine | |
EP1510254A2 (en) | Method and device for detecting an analyte in a fluid | |
AU2006235974B2 (en) | Methods and systems for monitoring molecular interactions | |
Andersson et al. | Lab-in-a-cell: Using Individual Cells as Experimentation Platforms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2360013 Country of ref document: CA Ref country code: CA Ref document number: 2360013 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 28533/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 593769 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000906956 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000906956 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 28533/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000906956 Country of ref document: EP |